Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
30.83
+0.04
+0.13%
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Virtus Kar Health Sciences Fund Class A (RAGHX)
Add to/Remove from a Portfolio
Add to Watchlist
AllianzGI Health Sciences A
30.83
+0.04
+0.13%
- Overview
- Profile
- Historical Data
- Holdings
RAGHX Overview
On this page you'll find an in-depth profile of Virtus Kar Health Sciences Fund Class A. Learn about the key management, total assets, investment strategy and contact information of RAGHX among other information.
Investment Strategy
The investment seeks long-term capital appreciation. The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.
Contact Information
Address
Greenfield, MA, 01301
Greenfield,MA 01301
United States
Greenfield,MA 01301
United States
Phone
+1 8002431574
Web
www.virtus.com
Top Executives
| Name | Title | Since | Until |
|---|---|---|---|
| Jon K Christensen | Portfolio Manager | 2022 | Now |
| Biography | Jon Christensen, CFA, Portfolio Manager | Mr. Christensen is a Portfolio Manager and a Senior Research Analyst with primary research responsibilities for the small and mid-capitalization health-care sector. Before joining Kayne Anderson Rudnick in 2001, Mr. Christensen was a Portfolio Manager and Senior Research Analyst for Doheny Asset Management and has approximately 18 years of equity research experience. He earned a B.S. in Mathematics/Applied Science from the University of California, Los Angeles, and an M.B.A. from the California State University, Long Beach. Mr. Christensen is a Chartered Financial Analyst charterholder. | ||
| Chris Armbruster | Portfolio Manager + Senior Research Analyst | 2022 | Now |
| Biography | Mr. Armbruster is a Portfolio Manager and Research Analyst at KAR with primary research responsibilities for the large-capitalization consumer discretionary, health care, and information technology sectors. Before joining Kayne Anderson Rudnick in 2013, Mr. Armbruster worked at B. Riley & Co. as an associate analyst covering special situations, and at Al Frank Asset Management as a vice president in equity research. | ||
| Christopher Chin | - | 2020 | 2022 |
| Peter Pirsch | Senior Portfolio Manager | 2018 | 2022 |
| Biography | Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder. | ||
| Bret Jones | Portfolio Manager | 2018 | 2019 |
| Biography | Mr. Jones is a portfolio manager, senior analyst and a director with Allianz Global Investors, which he joined in 2018. He is a member of the Health Care team covering health care services companies.He was previously a senior health care analyst at Pura Vida Investments; Oppenheimer; Brean Murray, Carret and Leerink Swann. Before that, Mr. Jones was an equity research associate at SG Cowen. He has a B.S., magna cum laude, in finance from Florida State University, and an M.B.A. from Kelley School of Business, Indiana University. Mr. Jones is a CFA charterholder. | ||
| John R. Schroer | Portfolio Manager | 2014 | 2018 |
| Biography | Mr. Schroer, CFA, is a portfolio manager and a director with Allianz Global Investors, which he joined in 2014. He is the sector head of the Health Care team. He was previously the president of Schroer Capital, L.P.; an equity analyst with HealthCor Management, L.P.; a managing member and portfolio manager for ITROS Capital Management, LLC; a global partner, senior vice president, and portfolio manager for INVESCO; and an analyst for Trust Company of the West. Mr. Schroer has a B.S. in history and international relations and an M.B.A. in finance from the University of Wisconsin. | ||
| Michael Dauchot | Portfolio Manager | 2005 | 2018 |
| Biography | Dr. Dauchot, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 1999. He is a member of the Health Care team, focusing on medical technology, life-science tools and diagnostics. He previously worked at Pequot Capital Management and BancBoston Robertson Stephens. Dr. Dauchot has a degree in chemistry from Case Western Reserve University, an M.B.A. from the Kellogg School of Management at Northwestern University and an M.D. from the University of Cincinnati College of Medicine. | ||
| Paul A. Wagner | Senior Research Analyst | 2008 | 2014 |
| Biography | Mr. Wagner, CFA, is a portfolio manager, a senior research analyst and a director with Allianz Global Investors, which he joined in 2006. He has biotechnology responsibilities for the US Health Care team and has 14 years of investment-industry experience. Mr. Wagner previously worked at PDL BioPharma in corporate and business development, and was a vice president and senior equity-research analyst in the biotechnology sector at Lehman Brothers. He has a B.S. in chemistry from the University of Wisconsin and a Ph.D. in chemistry from the California Institute of Technology. | ||
| Ken H. Tsuboi | Health Care team | 2007 | 2013 |
| Biography | Ken joined RCM in 1996, beginning his work on the Health Care team in 2000. Ken covers international healthcare companies, analyzing stocks for recommendation to the international portfolio management team. Previously, Mr. Tsuboi was an Asset Backed Analyst for RCM's fixed income team, where he was responsible for the implementation, strategy and evaluation of all asset- backed products. Prior to RCM, Ken was a Senior Portfolio Strategist at Payden & Rygel. | ||
| Dan Hunt | Member | 2008 | 2013 |
| Biography | Dan was responsible for proprietary and client-directed investment idea generation across sectors, with an emphasis on healthcare. He was appointed (as the youngest member) to SG Cowen’s seven-person Investment Policy Committee. Prior to joining SG Cowen, Dan worked for Thomson Financial/Carson in New York as a Senior Associate within Capital Markets Intelligence. Dan holds the Chartered Financial Analyst designation. | ||
Write your thoughts about Virtus Kar Health Sciences Fund Class A
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review